Dokuz Eylul University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Izmir Turkey (1982)

Organization Overview

First Clinical Trial
2008
NCT02631135
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

9 eylül university | Bandırma Onyedi Eylül University | DOKUZ EU | Dokuz Eylul University | Dokuz Eylül University | Dokuz Eylül University Faculty of Medicine | Dokuz Eylül University Faculty of Nursing | Dokuz Eylül University Institute of Health Sciences | Dokuz Eylul University Medical School | Dokuz Eylul University School of Medicine | Gorsev Yener | MS Outpatient Clinic, Dokuz Eylul University Hospital

Active Ingredients

Drugs in Phase 4 Trials (4)

dexmedetomidine (precedex) (1 trial)

propofol (diprivan) (1 trial)

remifentanil (ultiva) (2 trials)

rocuronium (zemuron) (1 trial)

Drugs in Phase 3 Trials (1)

azelastine (astelin) (1 trial)

Drugs in Phase 2 Trials (3)

methotrexate (1 trial)

methylprednisolone (medrol) (1 trial)

mometasone (elocon) (1 trial)

Drugs in Other Trials (1)

caffeine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Confusion (Phase 4)

Nasal Polyps (Phase 2)

Nasopharyngeal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 9